Regenerx Biopharmaceuticals (RGRX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Aug 31, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q1 FY2023, filed May 15, 2023. Each column of the statement tables below links to the filing it was taken from.
Regenerx Biopharmaceuticals (RGRX) reported $77K in revenue over the twelve months to Mar 31, 2023. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
A flat-revenue business is consuming capital while liabilities far exceed assets and annual losses deepen.
Revenue was unchanged from FY2019 through FY2022, yet the FY2022 net loss reached$1.7M while operating cash flow was-$941K ; that pairing indicates recorded activity is not yet funding the cost base. Financing supplied$1.8M in FY2021 but$0 in FY2022, so the latest cash profile no longer benefited from that offset.
At FY2022, liabilities of
FY2022 SG&A was
Financial Health Signals
Regenerx Biopharmaceuticals does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Regenerx Biopharmaceuticals scores -423.76, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($299) relative to total liabilities ($3.8M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Regenerx Biopharmaceuticals passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
Regenerx Biopharmaceuticals reported a net loss of $1.7M while operations used $941K of cash. With neither figure positive, the ratio between the two carries no quality signal.
Regenerx Biopharmaceuticals reported an operating loss of $1.4M against $326K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Regenerx Biopharmaceuticals generated $19K in revenue in Q1 2023. That is unchanged from the same quarter a year earlier. It is unchanged from the prior quarter.
Regenerx Biopharmaceuticals reported -$385K in net income in Q1 2023. This represents an increase of 9.2% from the same quarter a year earlier. Against the prior quarter it is up 1.5%.
Not reported for Q1 2023.
Cash & Balance Sheet
Regenerx Biopharmaceuticals held $102K in cash as of Q1 2023; long-term debt is not reported for that period.
Not reported for Q1 2023.
Not reported for Q1 2023.
Margins & Returns
Not reported for Q1 2023.
Not shown for Q1 2023: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q1 2023: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for Q1 2023.
Capital Allocation
None of these metrics is reported for Q1 2023.
RGRX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2310-Q | Q4'2210-Q | Q3'2210-Q | Q2'2210-Q | Q1'2210-Q | Q4'2110-K | Q3'2110-Q | Q2'2110-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $19K0.0% | $19K0.0% | $19K0.0% | $19K0.0% | $19K0.0% | $19K0.0% | $19K0.0% | $19K0.0% |
| R&D Expenses | N/A | $0 | $0-100.0% | $0-100.0% | $0-100.0% | $0-100.0% | $6K+1074.9% | $487-86.0% |
| SG&A Expenses | $324K-10.7% | $328K-15.2% | $304K-27.3% | $484K+75.3% | $363K+14.1% | $387K+25.0% | $418K+39.6% | $276K-31.1% |
| Operating Income | -$305K+11.3% | -$309K+16.0% | -$284K+29.6% | -$465K-80.6% | -$344K-14.8% | -$368K-26.5% | -$404K-44.1% | -$257K+33.2% |
| Interest Expense | $80K0.0% | $82K0.0% | $82K+0.9% | $81K0.0% | $80K0.0% | $82K+6.3% | $81K+55.8% | $81K+57.3% |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$385K+9.2% | -$391K+13.1% | -$367K+14.7% | -$546K-61.2% | -$424K-11.7% | -$450K-22.2% | -$430K-29.2% | -$339K+22.4% |
| EPS (Basic) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Diluted Shares (Avg) | 144M0.0% | N/A | 144M0.0% | 144M+7.4% | 144M+7.5% | N/A | 143M+7.5% | 134M+0.2% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, EBITDA.
RGRX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2310-Q | Q4'2210-Q | Q3'2210-Q | Q2'2210-Q | Q1'2210-Q | Q4'2110-K | Q3'2110-Q | Q2'2110-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $187K-80.6% | $382K-70.3% | $581K-63.5% | $736K-65.2% | $961K+204.5% | $1.3M+132.9% | $1.6M+468.4% | $2.1M+328.5% |
| Current Assets | $123K-86.9% | $307K-75.5% | $499K-67.8% | $726K-64.7% | $939K+274.1% | $1.3M+161.9% | $1.5M+684.6% | $2.1M+412.5% |
| Cash & Equivalents | $102K-89.0% | $291K-76.4% | $478K-68.6% | $707K-65.1% | $925K+345.7% | $1.2M+187.8% | $1.5M+997.5% | $2.0M+436.4% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $3.9M+11.5% | $3.8M+8.9% | $3.7M+7.5% | $3.6M-1.8% | $3.5M+2.7% | $3.5M+4.1% | $3.5M+6.1% | $3.7M+13.9% |
| Current Liabilities | $1.8M+346.5% | $554K+28.8% | $476K+14.1% | $433K-31.6% | $403K-6.7% | $430K+7.6% | $418K+21.0% | $633K+114.1% |
| Non-Current Liabilities | $2.1M-31.8% | $3.3M+6.1% | $3.2M+6.6% | $3.2M+4.4% | $3.1M+4.0% | $3.1M+3.7% | $3.0M+4.3% | $3.0M+3.7% |
| Total Equity | -$3.7M-45.9% | -$3.4M-54.5% | -$3.1M-68.1% | -$2.9M-84.2% | -$2.6M+17.7% | -$2.2M+21.0% | -$1.9M+37.4% | -$1.6M+43.0% |
| Retained Earnings | -$112.6M-1.5% | -$112.2M-1.6% | -$111.8M-1.6% | -$111.5M-1.7% | -$110.9M-1.5% | -$110.5M-1.5% | -$110.0M-1.4% | -$109.6M-1.3% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
RGRX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2310-Q | Q4'2210-Q | Q3'2210-Q | Q2'2210-Q | Q1'2210-Q | Q4'2110-K | Q3'2110-Q | Q2'2110-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$189K+38.2% | -$188K+35.7% | -$228K+47.0% | -$219K-756.2% | -$306K-26.4% | -$292K-39.9% | -$431K-80.3% | -$26K+91.3% |
| Stock-Based Compensation | $86K-1.5% | N/A | $86K-53.6% | $252K+307.4% | $88K+41.9% | N/A | $186K+151.3% | $62K-57.8% |
| Financing Cash Flow | N/A | N/A | N/A | $0-100.0% | $0-100.0% | $0-100.0% | -$72K | $1.8M+3227.6% |
Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
RGRX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2310-Q | Q4'2210-Q | Q3'2210-Q | Q2'2210-Q | Q1'2210-Q | Q4'2110-K | Q3'2110-Q | Q2'2110-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1588.9% | -1609.5% | -1482.3% | -2422.2% | -1791.7% | -1915.7% | -2105.5% | -1341.5% |
| Net Margin | -2007.3% | -2037.1% | -1909.9% | -2845.0% | -2209.7% | -2342.9% | -2239.9% | -1764.5% |
| Return on Assets | -206.2%-162.0pp | -102.3%-67.3pp | -63.1%-36.1pp | -74.2%-58.2pp | -44.1%+76.2pp | -35.0%+31.7pp | -27.0%+91.7pp | -16.0%+72.5pp |
| Current Ratio | 0.07-2.3x | 0.55-2.4x | 1.05-2.7x | 1.68-1.6x | 2.33+1.7x | 2.91+1.7x | 3.71+3.1x | 3.25+1.9x |
| Asset Turnover | 0.10+0.1x | 0.050.0x | 0.030.0x | 0.030.0x | 0.020.0x | 0.010.0x | 0.01-0.1x | 0.010.0x |
Not reported in any period shown, so not listed: Gross Margin, Return on Equity, Debt-to-Equity, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Note: Shareholder equity is negative (-$3.4M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.55), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Regenerx Biopharmaceuticals RGRX | FY2022 | $77K | -$1.7M | N/A | $299 | — |
| Neximmune, Inc. NEXI | FY2023 | N/A | -$32.3M | N/A | $4.1M | — |
| Eloxx Pharmaceut ELOX | FY2025 | $0 | -$6.0M | N/A | $55.9M | — |
| Effector Therapeutics Inc EFTR | FY2023 | $0 | -$35.8M | N/A | $612K | — |
Where Regenerx Biopharmaceuticals Ranks
Frequently Asked Questions
What is Regenerx Biopharmaceuticals's annual revenue?
Regenerx Biopharmaceuticals (RGRX) reported $77K in total revenue for fiscal year 2022. That is unchanged from the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Regenerx Biopharmaceuticals's revenue growing?
Regenerx Biopharmaceuticals (RGRX) revenue was essentially unchanged year-over-year, at $77K in fiscal year 2022 against $77K the year before.
Is Regenerx Biopharmaceuticals profitable?
No, Regenerx Biopharmaceuticals (RGRX) reported a net income of -$1.7M in fiscal year 2022.
What is Regenerx Biopharmaceuticals's operating cash flow?
Regenerx Biopharmaceuticals (RGRX) recorded an outflow of $941K in operating cash flow during fiscal year 2022, representing cash used by core business activities.
What are Regenerx Biopharmaceuticals's total assets?
Regenerx Biopharmaceuticals (RGRX) had $382K in total assets as of fiscal year 2022, including both current and long-term assets.
What is Regenerx Biopharmaceuticals's current ratio?
Regenerx Biopharmaceuticals (RGRX) had a current ratio of 0.55 as of fiscal year 2022, which is below 1.0, which may suggest potential liquidity concerns.
What is Regenerx Biopharmaceuticals's return on assets (ROA)?
Regenerx Biopharmaceuticals (RGRX) had a return on assets of -452.0% for fiscal year 2022, measuring how efficiently the company uses its assets to generate profit.
What is Regenerx Biopharmaceuticals's P/E ratio?
Regenerx Biopharmaceuticals (RGRX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to March 31, 2023). The market capitalization is $299 as of Aug 31, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Regenerx Biopharmaceuticals's price-to-sales ratio?
Regenerx Biopharmaceuticals (RGRX) trades at 0.0x sales, its market capitalization divided by revenue of $77K revenue, trailing 12 months to March 31, 2023. The market capitalization is $299 as of Aug 31, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Regenerx Biopharmaceuticals's liquidity compare with its operating cash outflow?
At the end of fiscal year 2022, Regenerx Biopharmaceuticals (RGRX) held $291K in cash, cash equivalents and investments, and reported an operating cash outflow of $941K over that year. Dividing the one by the other, the reported balance equals about 4 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is Regenerx Biopharmaceuticals's debt-to-equity ratio negative or not reported?
Regenerx Biopharmaceuticals (RGRX) has negative shareholder equity of -$3.4M as of fiscal year 2022, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Regenerx Biopharmaceuticals's Altman Z-Score?
Regenerx Biopharmaceuticals (RGRX) has an Altman Z-Score of -423.76, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Regenerx Biopharmaceuticals's Piotroski F-Score?
Regenerx Biopharmaceuticals (RGRX) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Regenerx Biopharmaceuticals's earnings high quality?
Regenerx Biopharmaceuticals (RGRX) reported a net loss of $1.7M while operations used $941K of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Regenerx Biopharmaceuticals cover its interest payments?
Regenerx Biopharmaceuticals (RGRX) reported an operating loss of $1.4M against $326K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.